Core Viewpoint - The collaboration between Innovent Biologics and Takeda Pharmaceutical aims to develop cancer treatment drugs, with a total deal value of $11.4 billion, setting a record for business development transactions in China's pharmaceutical industry [1] Group 1: Collaboration Details - The total amount of the collaboration is $11.4 billion, focusing on three drugs: IBI363 and IBI343 in Phase 3 clinical trials, and IBI3001 in Phase 1 [1] - Both companies will jointly advance the development of IBI363, with Takeda granted commercialization rights outside Greater China and the U.S. [1] - Takeda will also receive exclusive rights for IBI343 outside Greater China, and an exclusive option for IBI3001 in regions outside Greater China [1] Group 2: Strategic Implications - This partnership is expected to accelerate Innovent's global development in the fields of immuno-oncology (IO) and antibody-drug conjugates (ADC) [1] - The collaboration will explore the research potential for treatments targeting non-small cell lung cancer and colorectal cancer [1]